Jul 16, 2020 / 11:00AM GMT
Operator
Ladies and gentlemen, welcome to the Sobi presentation of the Q2 results. (Operator Instructions)
I will now hand over to Guido Oelkers, CEO. Please go ahead.
Guido Oelkers - Swedish Orphan Biovitrum AB(publ)-CEO&President
Yes. Good afternoon, everybody. It's really a pleasure to have you here at our Q2 webcast. And I think with this having said, I will be joined today by Henrik Stenqvist, our CFO; and Milan Zdravkovic, our Head of R&D. And I think forward-looking statement as per usual. And why don't we go right into the beef of the presentation.
Yes. So basically, this is a difficult environment, and I understand that we are one of the -- we are the first group of pharma companies presenting. And I think, therefore -- I think it may be worthwhile to understand what happened actually in this environment. And I just want to refer to U.S. data that I just -- we just got recently hold of. So basically, in the U.S., total prescription between end of May and beginning of June are down 6%
Q2 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Jul 16, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers